Boundless Bio (BOLD) Registration Filing summary

Company overview and business model

• Clinical-stage oncology company focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), which is implicated in 14–17% of cancer patients.

• Utilizes proprietary Spyglass platform to identify druggable targets in ecDNA biology and develop small molecule ecDNA-directed therapeutics (ecDTx).

• Lead candidate BBI-355, a CHK1 inhibitor, is in Phase 1/2 clinical trials, with proof-of-concept data expected in the second half of 2025.

• Pipeline includes a kinesin-targeting program and an ecDNA diagnostic (ECHO) for patient selection in clinical trials.

• All programs discovered internally, with global rights retained.

Use of proceeds and capital allocation

• Net proceeds will fund research and development of ecDTx, working capital, general corporate purposes, and further development of the ecDNA diagnostic and Spyglass platform.

• May allocate a portion to in-license, acquire, or invest in complementary businesses, technologies, products, or assets.

• Management has broad discretion over use of proceeds, which may vary from current intentions.

Risk factors and disclosures

• Investment involves a high degree of risk, including potential for immediate and substantial dilution, and future dilution from additional equity or convertible debt issuances.

• Management has broad discretion in use of proceeds, and investments may not yield favorable returns.

• Market price of shares may fluctuate, and investors may pay different prices at different times.

• Risks are detailed in the Annual Report on Form 10-K and other incorporated filings.